Effects of Endothelial
In their recent study, Rossi et al. (1) showed that the T786C polymorphism on the promoter region of the endothelial nitric oxide synthase (eNOS) gene modifies redox-sensitive inflammatory pathways, and may be a predictor for clinical outcome in high-risk patients with coronary atherosclerosis. Although this polymorphism was found to be in linkage disequilibrium with the functional polymorphism G894T (D= ϭ 0.3), the latter had no predictive value in this cohort, despite the results of a large meta-analysis suggesting the opposite (2) . However, the observation that the 894T/786T haplotype leads to a worse cardiovascular death-free survival supports the hypothesis of a more complex association between these polymorphisms and eNOS function.
We have recently shown (3) that the presence of the 894T allele is associated with higher levels of oxidized low-density lipoprotein and proinflammatory cytokines only under conditions of "biological stress," such as during the acute phase of myocardial infarction, an effect not observed in the same subjects 1 year after the event, or in healthy individuals. Moreover, the 894T allele seems to be associated with impaired endothelial function in high-risk patients (4) and in healthy smokers (5), but not in healthy, low-risk individuals (5) .
In the present study, Rossi et al. (1) actually introduce the hypothesis that the previously observed transient effect of the 894T allele on oxidative stress, inflammatory process, and endothelial function (3-5) could actually be due to its linkage disequilibrium with the 786T allele (which has been suggested to modify eNOS expression). However, this could be due to the complex interaction of both polymorphisms constituting the 894T/786T haplotype. The combination of low eNOS expression (induced by the 786T allele) and increased susceptibility of eNOS to proteolytic cleavage (induced by the 894T allele) (6) could lead to a combined effect on the associated phenotype of nitric oxide bioavailability, and the subsequent alterations of oxidative stress and inflammatory status. Therefore, further molecular studies are required to explore the transient behavior of eNOS genotypes/haplotypes, leading to a different phenotype, depending on the underlying disease state.
gene on cardiovascular mortality, Tanus-Santos et al. recalled that the former SNP alters the gene responsiveness to statins: statins would up-regulate eNOS expression (2) more potently in -786C homozygous (3) and therefore, these subjects would generate more NO while on statins than subjects with the other genotypes. Accordingly, atorvastatin increased NO availability and reduced inflammatory marker concentrations in CC, but not in TT healthy men (4). However, we found no significant interaction between statin treatment and the T-786C SNP affecting cardiovascular mortality (1) . Moreover, only a minority of our patients were on statins (5); therefore, this mechanistic explanation is unlikely.
As with Tanus-Santos et al., we also found that the T-786C SNP did not affect nitrite/nitrate levels; however, functional data (6) indicate that the T-786C SNP affects NO bioactivity by altering the gene responsiveness to shear stress (7). Thus, the "Janus" nature of eNOS might reveal itself under conditions of oxidant stress, leading to decreased plaque stability and cardiovascular events (1).
Antoniades et al. raised another appealing hypothesis: an interaction of the 786T with the 894T allele constituting the 894T/786T haplotype might lower eNOS expression and increase susceptibility of eNOS to proteolytic cleavage, resulting into transiently increased oxidant stress and inflammatory status during acute conditions (8) . However, the G894T SNP lies within a loop on the external surface of eNOS and does not make contact with either the active site of the enzyme, or the dymerization interface, suggesting that, if functional, this SNP could act by a mechanism independent of eNOS catalysis. Moreover, the increased susceptibility to cleavage of the Asp298-encoded eNOS enzyme has been shown to be artifactual (reviewed by Casas et al.) (9) . Therefore, whether the 894T allele bears functional consequences remains controversial. Nonetheless, the linkage disequilibrium of the T-786C and G894T SNP (1) can explain the association of the latter SNP with coronary heart disease (CHD), as we pointed out.
Antoniades et al. stated that an increased risk of CHD (odds ratio [OR] ϭ 1.31) for the 894T allele carriers was reported; however, the excess risk deriving from meta-analysis of cross-sectional association studies, which are prone to stratification biases, should be viewed cautiously. In fact, a much larger meta-analysis led to a markedly reduced estimate of risk (OR ϭ 1.17) (9) .
Consistent with prospective study results in high-risk patients (1,10), we found no evidence for a prognostic effect of the 894T allele. Thus, even if the 894T homozygosity would imply a blunted NO production and/or higher levels of oxidized low-density lipoprotein and proinflammatory cytokines during acute coronary events, overall prospective cohort studies show no prognostic effect in high-risk patients.
Finally, although underlying the fact that intriguing results such as ours are crucial for generating novel hypotheses, we agree that the elucidation of the complex interplay between the eNOS gene haplotypes and environmental factors deserves further research. Rumberger (2) suggests medico-legal and moral imperatives to seek noncardiac pathology. The patient's entire chest and upper abdomen have been irradiated, after all, and the imaging data are there awaiting reconstruction. Although this approach seems very reasonable, I believe we need to keep an open mind, recognizing the absence of hard evidence that the pursuit of extracardiac pathology leads to overall improved patient outcomes. Much of the noncardiac pathology, such as liver and renal cysts, is relatively unimportant and probably unrelated to the symptom of chest pain. With regard to more serious pathology, several questions arise: When found, are the newly discovered malignancies curable or amenable to treatment that prolongs life or improves quality of
